The lancet oncology
-
The lancet oncology · Mar 2004
Review Historical ArticleOestrogen receptor beta: what it means for patients with breast cancer.
Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.
-
Events in the past 10-15 years have meant that Iraq's once highly sophisticated health-care system has fallen to rack and ruin. To fight the very low morale, Iraqi people are making use of many approaches, some of which are unconventional, such as circus entertainment to raise spirits in paediatric wards. This Reportage looks at the events that have lead to the current health-care crisis in Iraq through the eyes of those living and working there. It is based on interviews done by Jo Wilding, an independent humanitarian activist and writer working on various grassroots rehabilitation and solidarity projects in Iraq, in Al Mansour teaching hospital, Shahid Adnan hospital, the centre for Nuclear Medicine, and the Ministry of Health in Baghdad.
-
The lancet oncology · Mar 2004
ReviewRole of imbalance between neutrophil elastase and alpha 1-antitrypsin in cancer development and progression.
Neutrophil elastase and alpha 1-antitrypsin are a pair of protease and protease inhibitor counterparts. The imbalance between the two counterparts is generally thought to cause tissue damage, which could create a favourable tissue environment for carcinogens and tumour progression. ⋯ Several mechanisms of carcinogenesis have been postulated. Excess neutrophil elastase might facilitate cancer development by causing tissue damage and air trapping, which foster longer carcinogen exposure, might promote cancer progression by degrading the intercellular matrix barrier, and might directly lead to cancer development through the tumour-necrosis-factor signalling pathway.